Merck & Co., Inc. (MRK) EPS CAGR:7.99%(TTM)
The eps cagr for Merck & Co., Inc. (MRK) is +7.99% over the latest trailing 12-month period. EPS CAGR uses precomputed diluted earnings history where available.
The eps cagr for Merck & Co., Inc. (MRK) stock is 7.99% over the past 12 months. The 3 year average growth rate is 8.40% and the 5 year cagr is 21.21%. EPS (Earnings Per Share) CAGR measures how Merck & Co., Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
MRK EPS CAGR Chart
Merck & Co., Inc. (MRK)
MRK EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $6.76 | $7.30 | +$0.54 | +7.99% | +7.99% |
| 2024 | $0.14 | $6.76 | +$6.62 | +4728.57% | +4728.57% |
| 2023 | $5.73 | $0.14 | $-5.59 | -97.56% | -97.56% |
| 2022 | $5.16 | $5.73 | +$0.57 | +11.05% | +11.05% |
| 2021 | $2.79 | $5.16 | +$2.37 | +84.95% | +84.95% |
| 2020 | $3.84 | $2.79 | $-1.05 | -27.34% | -27.34% |
| 2019 | $2.40 | $3.84 | +$1.44 | +60.00% | +60.00% |
| 2018 | $0.95 | $2.40 | +$1.45 | +152.63% | +152.63% |
| 2017 | $2.07 | $0.95 | $-1.12 | -54.11% | -54.11% |
| 2016 | $1.60 | $2.07 | +$0.47 | +29.37% | +29.37% |
| 2015 | $4.20 | $1.60 | $-2.60 | -61.90% | -61.90% |
| 2014 | $1.50 | $4.20 | +$2.70 | +180.00% | +180.00% |
| 2013 | $2.20 | $1.50 | $-0.70 | -31.82% | -31.82% |
| 2012 | $2.06 | $2.20 | +$0.14 | +6.80% | +6.80% |
| 2011 | $0.28 | $2.06 | +$1.78 | +635.71% | +635.71% |
| 2010 | $4.15 | $0.28 | $-3.87 | -93.25% | -93.25% |
| 2009 | $3.65 | $4.15 | +$0.50 | +13.70% | +13.70% |
| 2008 | $-1.04 | $3.65 | +$4.69 | +0.00% | N/A |
| 2007 | $2.04 | $-1.04 | $-3.08 | -150.98% | N/A |
| 2006 | $2.11 | $2.04 | $-0.07 | -3.32% | -3.32% |
| 2005 | $2.63 | $2.11 | $-0.52 | -19.77% | -19.77% |
| 2004 | $2.97 | $2.63 | $-0.34 | -11.45% | -11.45% |
| 2003 | $3.17 | $2.97 | $-0.20 | -6.31% | -6.31% |
| 2002 | $3.18 | $3.17 | $-0.01 | -0.31% | -0.31% |
| 2001 | $2.96 | $3.18 | +$0.22 | +7.43% | +7.43% |
| 2000 | $2.51 | $2.96 | +$0.45 | +17.93% | +17.93% |
| 1999 | $2.21 | $2.51 | +$0.30 | +13.57% | +13.57% |
| 1998 | $1.92 | $2.21 | +$0.29 | +15.10% | +15.10% |
| 1997 | $1.60 | $1.92 | +$0.32 | +20.00% | +20.00% |
Quarterly EPS — QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $-1.72 | -243.3% | -185.6% |
| Q4 2025 | $1.20 | -48.3% | -18.9% |
| Q3 2025 | $2.32 | +31.8% | +85.6% |
| Q2 2025 | $1.76 | -12.4% | -18.1% |
| Q1 2025 | $2.01 | +35.8% | +6.9% |
| Q4 2024 | $1.48 | +18.4% | +408.3% |
| Q3 2024 | $1.25 | -41.9% | -33.2% |
| Q2 2024 | $2.15 | +14.4% | +191.5% |
| Q1 2024 | $1.88 | +491.7% | +69.4% |
| Q4 2023 | $-0.48 | -125.7% | -140.3% |
| Q3 2023 | $1.87 | +179.6% | +46.1% |
| Q2 2023 | $-2.35 | -311.7% | -250.6% |
| Q1 2023 | $1.11 | -6.7% | -34.7% |
| Q4 2022 | $1.19 | -7.0% | -20.1% |
| Q3 2022 | $1.28 | -17.9% | -29.3% |
| Q2 2022 | $1.56 | -8.2% | +155.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis